Table 3. Serotype-specific contributions (%) to paediatric IPD cases in settings that have introduced PCV10 or PCV13.
| OVERALL (N = 20) |
LATIN AMERICA (N = 1†) |
NORTH AMERICA (N = 4) |
EUROPE (N = 8) |
WESTERN PACIFIC (N = 4) |
AFRICA (N = 1) |
EASTERN MEDITERRANEAN (N = 2) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCV7 | 12.5 (8.8–17.7) | 32.5 (25.5–41.3) | 3.4 (2.5–4.5) | 4.4 (3.3–5.7) | 5.8 (1.6–21.1) | * | 25.5 (22.3–29.2) | ** | 62.6 (46.3–84.7) | |||
| PCV10-7 | 9.2 (6.9–12.2) | 10.1 (5–20.4) | 7.9 (4.5–13.9) | 10.1 (6.6–15.4) | 4.6 (1.5–14) | * | 9.8 (7.9–12.2) | ** | 8.9 (1–81.8) | |||
| PCV13 | 49.1 (42.3–56.9) | 71.2 (65.9–77) | 37.3 (25.4–54.7) | 27.9 (19.9–39.1) | 48.7 (31.6–74.8) | * | 57.3 (52.4–62.6) | ** | 91 (78.2–100) | |||
| 19A | 14.2 (11.1–18.3) | 12.5 (7.7–20.2) | 20.8 (13.3–32.6) | 11.3 (7.6–17) | 29.6 (20.3–43.1) | * | 11.4 (9.3–13.9) | ** | 6.2 (3.4–11.2) | |||
| 3 | 5.3 (4.2–6.7) | 6.7 (4.7–9.7) | 6.1 (3.9–9.3) | 4.7 (3.6–6.1) | 7.1 (3.4–14.9) | * | 2 (1.3–3.2) | * | 2.2 (0.8–5.8) | |||
| 6A | 3.2 (2.1–4.9) | 5.5 (4.2–7.1) | ** | 1 (0.6–1.8) | 1 (0.5–2) | * | 0.5 (0.1–3.8) | * | 8.5 (6.8–10.8) | ** | 4.9 (2.2–11.3) | |
| NON-PCV13 | 42.2 (36.1–49.5) | 28.5 (23.4–34.7) | 57.8 (41.6–80.4) | 71.9 (63.1–82) | 45.9 (30.9–68.2) | * | 42.7 (38.5–47.4) | * | 9.2 (3.7–22.9) | |||
| 22F | 5.3 (4.2–6.7) | 2.3 (1.4–3.7) | 6.9 (4.5–10.4) | 5.2 (3.6–7.5) | 7.4 (4.6–12) | − | − | |||||
| 12F | 4.3 (3.5–5.3) | 4 (2.8–5.7) | ** | 3.3 (1.3–8.3) | 5.6 (4.4–7) | − | * | 4 (2.9–5.6) | * | 1.3 (0.2–9.1) | ||
| 33F | 4.5 (3.4–5.9) | ** | 2 (0.8–4.8) | 4.9 (2.2–10.8) | 4.9 (3.3–7.4) | 4.3 (2.5–7.5) | − | − | ||||
| 24F | 4.2 (2.6–6.8) | 2.4 (1.6–3.8) | − | 6.7 (3.8–11.9) | * | 3.9 (0.1–12.4) | − | − | ||||
| 15C | 4 (3.1–5) | 1.5 (0.8–2.7) | 3.9 (2.4–6.5) | 5.9 (4.4–7.8) | * | 4.3 (2.2–8.7) | − | − | ||||
| 15B | 3.7 (3.1–4.4) | 2.5 (1.5–4.3) | 4.2 (2.3–7.8) | 3.7 (2.6–5.2) | ** | 3.3 (1.7–6.7) | * | 4.3 (3.1–5.9) | − | |||
| 23B | 3.4 (2.6–4.3) | 2.4 (1.4–4.1) | 3 (2–4.4) | 4.1 (2.6–6.5) | ** | 3.9 (2.1–7.3) | − | * | 1.3 (0.2–9.1) | |||
| 10A | 3.4 (2.2–5.4) | 1.3 (0.8–2.3) | ** | 2.6 (1.7–3.8) | 6.7 (3.7–12.4) | ** | 3 (1.6–5.8) | − | − | |||
| 38 | 3.4 (2.4–4.8) | 1.8 (0.6–5.5) | ** | 5 (1.7–14.3) | 3.2 (1.8–5.6) | ** | 0.7 (0.2–2.6) | − | − | |||
| 15A | 2.9 (1.9–4.4) | 1.4 (0.8–2.5) | 3.3 (1.5–7.4) | 3.9 (1.9–7.9) | ** | 3 (0.2–38.9) | − | − | ||||
| 35B | 2.6 (1.8–3.8) | 1.2 (0.2–6.4) | 4.5 (1.7–11.4) | 1.4 (0.9–2.3) | ** | 3.9 (2.2–6.9) | − | − | ||||
| 6C | 2.4 (1.8–3) | 2.4 (1.6–3.7) | 2.3 (1.6–3.3) | 1.6 (0.7–3.6) | 3 (1.2–7.1) | − | − | |||||
| 8 | 2.2 (1.3–3.8) | 1.2 (0.6–2.3) | ** | 1.5 (0.9–2.5) | 2.9 (1.3–6.2) | * | 3.8 (1.2–11.9) | * | 8.3 (6.6–10.5) | * | 1.3 (0.2–9.1) | |
| 11A | 2 (1.6–2.6) | 2.2 (1.5–3.3) | ** | 2.5 (1.6–3.7) | 1.7 (1.1–2.6) | ** | 0.7 (0.2–2.6) | − | − | |||
| 23A | 2 (1.6–2.6) | 2 (1.2–3.6) | 2.2 (1.5–3.2) | 1.6 (1–2.5) | 2.4 (1.1–5) | − | * | 2.6 (0.6–10.2) | ||||
| 9N | 1.3 (1–1.8) | 1.3 (0.6–2.8) | ** | 1.3 (0.7–2.4) | 1.3 (0.7–2.4) | ** | 1.5 (0.5–4.7) | * | 1.8 (1.1–3) | − | ||
Estimates of serotype-specific contributions to IPD in children (% 95%CI) reported are based on random effects model from meta-analysis of 3 or more studies, unless indicated [one study (*) or two (**)].–indicates no data reported.
†10 countries from the SIREVA surveillance network. Meta-analyses were conducted individually, thus the sum of each of the serotypes in a category may exceed 100%